Drug Profile
NCX 6560
Alternative Names: NCX-6560Latest Information Update: 08 Oct 2012
Price :
$50
*
At a glance
- Originator NicOx
- Class Cardiovascular therapies; Heptanoic acids; Pyrroles
- Mechanism of Action HMG-CoA reductase inhibitors; Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes
Most Recent Events
- 27 Jul 2012 Discontinued - Phase-I for Acute coronary syndromes in France (PO)
- 22 Nov 2010 NCX 6560 is available for licensing as of 22 Nov 2010. http://www.nicox.com/update/home_engl.html
- 18 Nov 2010 Updated efficacy and adverse events data from a phase Ib trial presented at the 83rd Annual Scientific Sessions of the American Heart Association (AHA-2010)